

WEEKLY RESPIRATORY PATHOGENS SURVEILLANCE REPORT

SOUTH AFRICA WEEK 34 2021

CONTENTS

Surveillance programme description	2
Comments	3
Systematic Influenza-like illness (ILI) surveillance	4-7
Influenza	
Respiratory syncytial virus	
SARS-CoV-2	
Influenza-like illness (ILI) Viral Watch	8-11
Influenza	
SARS-CoV-2	
National syndromic surveillance for pneumonia	12-16
Influenza	
Respiratory syncytial virus	
SARS-CoV-2	
Summary of laboratory confirmed SARS-CoV-2 cases	17-18

CUMULATIVE DATA FROM



HIGHLIGHTS: WEEK 34

- RSV activity remains below seasonal threshold in both influenza-like illness (ILI) and pneumonia surveillance programmes.

- Seven new cases of influenza from North West (n=1), Gauteng (n=4) and Western Cape (n=2) surveillance sites were detected in week34. To date, 77 influenza cases have been detected from Gauteng, Western Cape, North West, Eastern Cape, Mpumalanga and KwaZulu-Natal sentinel surveillance sites. The influenza season has not started.

- From 2 March 2020 to 29 August 2021, a total of 2 679 COVID-19 cases were detected from all surveillance programmes. A decline in detection rate has been noted in pneumonia surveillance programme in week34, whereas ILI programme had a slight increase. Of the 1 706 hospitalised COVID-19 cases reported with available data on outcome, 288 (16%) died.

INFLUENZA, RESPIRATORY SYNCYTIAL VIRUS AND SARS-CoV-2 SURVEILLANCE REPORT

WEEK 34 2021

REPORTING PERIOD 4 JANUARY 2021 TO 29 AUGUST 2021

PROGRAMME DESCRIPTIONS

Programme	Influenza-like illness (ILI)	Viral Watch	National syndromic surveillance for pneumonia
Start year	2012	1984	2009
Provinces*	KZ NW WC** MP***	EC FS GP LP MP NC NW WC	GP KZ MP NW WC
Type of site	Primary health care clinics	General practitioners	Public hospitals
Case definition	<p>ILI: An acute respiratory illness with a temperature ($\geq 38^{\circ}\text{C}$) and cough, & onset ≤ 10 days</p> <p>Suspected pertussis Any person with an acute cough illness lasting ≥ 14 days (or cough illness of any duration for children < 1 year), without a more likely diagnosis AND one or more of the following signs or symptoms:</p> <ul style="list-style-type: none"> • paroxysms of coughing, • or inspiratory “whoop”, • or post-tussive vomiting • or apnoea in children < 1 year; <p>OR</p> <p>Any person in whom a clinician suspects pertussis</p> <p>Suspected SARS-CoV-2 Any person presenting with an acute (≤ 14 days) respiratory tract infection or other clinical illness compatible with COVID-19[§]</p>	<p>ILI: An acute respiratory illness with a temperature ($\geq 38^{\circ}\text{C}$) and cough, & onset ≤ 10 days</p> <p>Suspected SARS-CoV-2 Any person presenting with an acute (≤ 14 days) respiratory tract infection or other clinical illness compatible with COVID-19[§]</p>	<p>SRI: Acute (symptom onset ≤ 10 days) or chronic (symptom onset > 10) lower respiratory tract infection</p> <p>Suspected pertussis Any person with an acute cough illness lasting ≥ 14 days (or cough illness of any duration for children < 1 year), without a more likely diagnosis AND one or more of the following signs or symptoms:</p> <ul style="list-style-type: none"> • paroxysms of coughing, • or inspiratory “whoop”, • or post-tussive vomiting • or apnoea in children < 1 year; <p>OR</p> <p>Any person in whom a clinician suspects pertussis.</p> <p>Suspected SARS-CoV-2 Any person admitted with a physician-diagnosis of suspected COVID-19 and not meeting SRI case definition.</p>
Specimens collected	Oropharyngeal & nasopharyngeal swabs	Throat and/or nasal swabs or Nasopharyngeal swabs	Oropharyngeal & nasopharyngeal swabs
Main pathogens tested****	INF RSV BP SARS-CoV-2	INF RSV BP SARS-CoV-2	INF RSV BP SARS-CoV-2

Epidemic Threshold

Thresholds are calculated using the Moving Epidemic Method (MEM), a sequential analysis using the R Language, available from: <http://CRAN.R-project.org/web/package=mem> designed to calculate the duration, start and end of the annual influenza epidemic. MEM uses the 40th, 90th and 97.5th percentiles established from available years of historical data to calculate thresholds of activity. Thresholds of activity for influenza and RSV are defined as follows: Below seasonal threshold, Low activity, Moderate activity, High activity, Very high activity. For influenza, thresholds from outpatient influenza like illness (Viral Watch Programme) are used as an indicator of disease transmission in the community and thresholds from pneumonia surveillance are used as an indicator of impact of disease.

* EC: Eastern Cape; FS: Free State; GP: Gauteng; KZ: KwaZulu-Natal; LP: Limpopo; MP: Mpumalanga; NC: Northern Cape; NW: North West; WC: Western Cape

**Started in 2019

***Started in November 2020

****INF: influenza virus; RSV: respiratory syncytial virus; BP: *Bordetella pertussis*; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2

§Symptoms include ANY of the following respiratory symptoms: cough, sore throat, shortness of breath, anosmia (loss of sense of smell) or dysgeusia (alteration of the sense of taste), with or without other symptoms (which may include fever, weakness, myalgia, or diarrhoea)

INFLUENZA, RESPIRATORY SYNCYTIAL VIRUS AND SARS-CoV-2 SURVEILLANCE REPORT

WEEK 34 2021

REPORTING PERIOD 2 MARCH 2020 TO 29 AUGUST 2021

COMMENTS

Influenza

The influenza 2021 season has not started. Since the first influenza positive case of 2021 was detected in pneumonia surveillance in week 9 of 2021 (week ending on the 07 March 2021), sporadic cases have been reported from week 16 to date. Of the 77 influenza cases detected in surveillance sites in 2021, the majority (n=66, 86%) were influenza B/Victoria.

ILI programme: In 2021 to date, specimens from 1 217 patients meeting ILI case definition were received from 4 ILI sites. Influenza was detected in 10 (1%) patients, of which eight (80%) were influenza B(Victoria) and two (20%) were influenza B (lineage inconclusive). (Figure 1 and Table 1).

Viral Watch programme: In 2021 to date, specimens were received from 166 patients from Viral Watch sites in 5 of the 8 provinces participating in surveillance. Influenza was detected in nine (5%) patients, of which five (56%) were influenza B (Victoria), and four (44%) influenza B (lineage inconclusive) (Figure 5 and Table 4).

Pneumonia surveillance: Since the beginning of 2021, specimens from 4 118 patients with severe respiratory illness (SRI) were received from the 6 sentinel sites. Influenza was detected in 43 (1%) patients, of which four (9%) were influenza A(H3N2), 38 (88%) influenza B (Victoria) and one (2%) was influenza B (lineage inconclusive). (Figure 9 and Table 7).

In addition, influenza B (Victoria) was detected in 15 of 675 (2%) from patients who met suspected SARS-CoV-2 case definition but did not meet the pneumonia/ILI surveillance case definitions.

Respiratory syncytial virus

In 2021 to date, RSV detection has been reported from all surveillance programmes, activity remains below seasonal threshold.

ILI programme: In 2021 to date, 1 217 specimens were tested and RSV was detected in specimens of 73 (6%) patients.

Viral Watch programme: In 2021 to date, 166 specimens were tested and RSV was detected in specimens of six (4%) patients.

Pneumonia surveillance: Since the beginning of 2021, 4 118 specimens were tested and RSV was detected in specimens of 391 (9%) patients.

In addition, RSV was detected in 21 of 675 (3%) specimens from patients who met suspected SARS-CoV-2 case definition but did not meet the pneumonia/ILI surveillance case definitions.

SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2)

Testing for SARS-CoV-2 was initiated in all three surveillance programmes in week 10 of 2020 (week starting 2 March 2020).

ILI programme: From March 2020 to date, specimens from 2 528 patients were tested and SARS-CoV-2 was detected in 526 (21%) patients.

Viral Watch programme: From March 2020 to date, specimens were tested from 445 patients and SARS-CoV-2 was detected in 83 (19%) patients.

Pneumonia surveillance: From March 2020 to date, specimens from 8 133 patients with severe respiratory illness (SRI) were tested and SARS-CoV-2 was detected in 1 891 (23%) patients.

In addition, SARS-CoV-2 was detected in 179 of 878 (20%) specimens from patients who met suspected SARS-CoV-2 case definition but did not meet the pneumonia/ILI surveillance case definitions.

INFLUENZA, RESPIRATORY SYNCYTIAL VIRUS AND SARS-CoV-2 SURVEILLANCE REPORT

WEEK 34 2021

REPORTING PERIOD 4 JANUARY 2021 TO 29 AUGUST 2021

INFLUENZA-LIKE ILLNESS (ILI) SURVEILLANCE PRIMARY HEALTH CARE CLINICS




Figure 1. Number of positive samples* by influenza subtype and lineage** and detection rate*** by week

*Specimens from patients with influenza-like illnesses at 5 sentinel sites in 4 provinces

**Influenza was detected from 11 of 530 (2%), all were influenza B(Victoria) from patients who met suspected SARS-CoV-2 case definition but did not meet Influenza-like illness (ILI) case definition. These are not included in the epidemiological curve.

***Only reported for weeks with >10 specimens submitted

Inconclusive: insufficient viral load in sample and unable to characterise further

B lineage pending results: means influenza B results for lineage are pending

Table 1. Cumulative number of influenza subtype and lineage** and total number of samples tested by clinic and province

Clinic (Province)	A(H1N1) pdm09	A(H3N2)	A subtype inconclusive	B/Victoria	B/Yamagata	B lineage inconclusive	B lineage pending results***	Total samples
Agincourt (MP)	0	0	0	0	0	0	0	171
Eastridge (WC)	0	0	0	0	0	0	0	182
Edendale Gateway (KZ)	0	0	0	3	0	2	0	146
Jouberton (NW)	0	0	0	5	0	0	0	593
Mitchell's Plain (WC)	0	0	0	0	0	0	0	125
Total:	0	0	0	8	0	2	0	1 217

KZ: KwaZulu-Natal; NW: North West; WC: Western Cape; MP: Mpumalanga

Inconclusive: insufficient viral load in sample and unable to characterise further

**Influenza was detected from 11 of 530 (2%), all were influenza B(Victoria), patients who met suspected SARS-CoV-2 case definition but did not meet Influenza-like illness (ILI) case definition. These are not included in the table.

***influenza B lineage results are pending

INFLUENZA, RESPIRATORY SYNCYTIAL VIRUS AND SARS-CoV-2 SURVEILLANCE REPORT

WEEK 34 2021

REPORTING PERIOD 4 JANUARY 2021 TO 29 AUGUST 2021

INFLUENZA-LIKE ILLNESS (ILI) SURVEILLANCE PRIMARY HEALTH CARE CLINICS




Figure 2. Number of samples testing positive for respiratory syncytial virus** by subgroup and detection rate by week

Inconclusive: insufficient viral load in sample and unable to characterise further
 RSV AB: Both RSV A and B subgroup identified
 RSV subgroup pending: means RSV results for subgroups are pending

**RSV was detected from 15 of 530 (3%) specimens from patients who met suspected SARS-CoV-2 case definition but did not meet influenza-like illness (ILI) case definition. These are not included in the epidemiological curve.

Table 2. Cumulative number of respiratory syncytial virus subgroups** identified and total number of samples tested by clinic and province

Clinic (Province)	RSVA	RSVB	RSVAB	RSV subgroup inconclusive	RSV subgroup pending*	Total samples
Agincourt (MP)	11	7	1	0	0	171
Eastridge (WC)	22	1	1	0	1	182
Edendale Gateway (KZ)	1	6	0	0	0	146
Jouberton (NW)	2	17	0	1	0	593
Mitchell's Plain (WC)	2	0	0	0	0	125
Total	38	31	2	1	1	1 217

KZ: KwaZulu-Natal; NW: North West; WC: Western Cape; MP: Mpumalanga
 Inconclusive: insufficient viral load in sample and unable to characterise further
 RSV AB: Both RSV A and B subgroup identified
 *RSV results for subgroups are pending

**RSV was detected from 15 of 530 (3%) specimens from patients who met suspected SARS-CoV-2 case definition but did not meet influenza-like illness (ILI) case definition. These are not included in the table.

INFLUENZA, RESPIRATORY SYNCYTIAL VIRUS AND SARS-CoV-2 SURVEILLANCE REPORT

WEEK 34 2021

REPORTING PERIOD 4 JANUARY 2021 TO 29 AUGUST 2021

INFLUENZA-LIKE ILLNESS (ILI) SURVEILLANCE PRIMARY HEALTH CARE CLINICS




Figure 3. Number of samples testing positive for respiratory syncytial virus* by province and detection rate by week

*RSV was detected from 15 of 530 (3%) specimens from patients who met suspected SARS-CoV-2 case definition but did not meet influenza-like illness (ILI) case definition. These are not included in the epidemiological curve.

INFLUENZA, RESPIRATORY SYNCYTIAL VIRUS AND SARS-CoV-2 SURVEILLANCE REPORT

WEEK 34 2021

REPORTING PERIOD 2 MARCH 2020 TO 29 AUGUST 2021

INFLUENZA-LIKE ILLNESS (ILI) SURVEILLANCE PRIMARY HEALTH CARE CLINICS




Figure 4. Number of samples testing positive for SARS-CoV-2*[§] by province and detection rate by week

*Specimens from patients with influenza-like illnesses at 5 sentinel sites in 4 provinces

[§]SARS-CoV-2 was detected in 143 of 662 (22%) specimens from patients who met suspected SARS-CoV-2 case definition but did not meet influenza-like illness (ILI) case definition. These are not included in the epidemiological curve.

Table 3. Cumulative number of SARS-CoV-2** identified and total number of samples tested by clinic and province

Clinic (Province)	SARS-CoV-2 positive	Total samples tested
Agincourt (MP)	60	201
Eastridge (WC)	57	671
Edendale Gateway (KZ)	61	289
Jouberton (NW)	264	913
Mitchell's Plain (WC)	84	454
Total:	526	2 528

KZ: KwaZulu-Natal; NW: North West; WCP: Western Cape; MP: Mpumalanga (started enrolling on the 10th November 2020)

**SARS-CoV-2 was detected in 143 of 662 (22%) specimens from patients who met suspected SARS-CoV-2 case definition but did not meet influenza-like illness (ILI) case definition. These are not included in the table.

INFLUENZA, RESPIRATORY SYNCYTIAL VIRUS AND SARS-CoV-2 SURVEILLANCE REPORT

WEEK 34 2021

REPORTING PERIOD 4 JANUARY 2021 TO 29 AUGUST 2021

INFLUENZA-LIKE ILLNESS (ILI) SURVEILLANCE VIRAL WATCH




Figure 5. Number of positive samples* by influenza subtype and lineage and detection rate** by week

*Specimens from patients with Influenza-like illnesses at 92 sentinel sites in 8 provinces

** Only reported for weeks with >10 specimens submitted

Inconclusive: insufficient viral load in sample and unable to characterise further

Table 4. Cumulative number of influenza subtype and lineage and total number of samples tested by province

Province	A(H1N1) pdm09	A(H3N2)	A subtype inconclusive	B/ Victoria	B/ Yamagata	B lineage inconclusive	B lineage pending results*	Total samples
Eastern Cape	0	0	0	1	0	0	0	1
Free State	0	0	0	0	0	0	0	0
Gauteng	0	0	0	4	0	4	0	139
Limpopo	0	0	0	0	0	0	0	0
Mpumalanga	0	0	0	0	0	0	0	2
North West	0	0	0	0	0	0	0	2
Northern Cape	0	0	0	0	0	0	0	0
Western Cape	0	0	0	0	0	0	0	22
Total:	0	0	0	5	0	4	0	166

Inconclusive: insufficient viral load in sample and unable to characterise further

From 04 January 2021 to date, no patients were tested for influenza at the time of entry into South Africa following travel abroad.

Patients known to have acquired influenza abroad are not included in the table or epidemiological curve.

INFLUENZA, RESPIRATORY SYNCYTIAL VIRUS AND SARS-CoV-2 SURVEILLANCE REPORT

WEEK 34 2021

REPORTING PERIOD 4 JANUARY 2021 TO 29 AUGUST 2021

INFLUENZA-LIKE ILLNESS (ILI) SURVEILLANCE VIRAL WATCH



Figure 6. ILI surveillance (Viral Watch) percentage influenza detections and epidemic thresholds*

*Thresholds based on 2010-2019 data

INFLUENZA, RESPIRATORY SYNCYTIAL VIRUS AND SARS-CoV-2 SURVEILLANCE REPORT

WEEK 34 2021

REPORTING PERIOD 4 JANUARY 2021 TO 29 AUGUST 2021

INFLUENZA-LIKE ILLNESS (ILI) SURVEILLANCE VIRAL WATCH




Figure 7. Number of samples testing positive for RSV*, and detection rate by week

*Specimens from patients with Influenza-like illnesses at 92 sentinel sites in 8 provinces

Table 5. Cumulative number of RSV positive cases identified and total number of samples tested by province

Province	RSV positive	Total samples tested
Eastern Cape	0	1
Free State	0	0
Gauteng	4	139
Limpopo	0	0
Mpumalanga	0	2
North West	0	2
Northern Cape	0	0
Western Cape	2	22
Total:	6	166

INFLUENZA, RESPIRATORY SYNCYTIAL VIRUS AND SARS-CoV-2 SURVEILLANCE REPORT

WEEK 34 2021

REPORTING PERIOD 2 MARCH 2020 TO 29 AUGUST 2021

INFLUENZA-LIKE ILLNESS (ILI) SURVEILLANCE VIRAL WATCH




Figure 8. Number of samples testing positive for SARS-CoV-2*, and detection rate by week

*Specimens from patients with Influenza-like illnesses at 92 sentinel sites in 8 provinces

Table 6. Cumulative number of SARS-CoV-2 identified and total number of samples tested by province

Hospital (Province)	SARS-CoV-2 positive	Total samples
Eastern Cape	1	5
Free State	1	14
Gauteng	65	299
Limpopo	0	2
Mpumalanga	1	7
North West	0	2
Northern Cape	0	2
Western Cape	15	114
Total:	83	445

INFLUENZA, RESPIRATORY SYNCYTIAL VIRUS AND SARS-CoV-2 SURVEILLANCE REPORT

WEEK 34 2021

REPORTING PERIOD 4 JANUARY 2021 TO 29 AUGUST 2021

NATIONAL SYNDROMIC SURVEILLANCE FOR PNEUMONIA




Figure 9. Number of positive samples* by influenza subtype and lineage** and detection rate*** by week

*Specimens from patients hospitalised with pneumonia at 7 sentinel sites in 5 provinces

**Influenza B (Victoria) was detected in four (3%) of 145 specimens from patients who met suspected SARS-CoV-2 case definition but did not meet pneumonia (SRI) case definition. These are not included in the epidemiological curve.

***Only reported for weeks with >10 specimens submitted

Inconclusive: insufficient viral load in sample and unable to characterise further
B lineage pending results: influenza B results for lineage are pending

Table 7. Cumulative number of identified influenza subtype and lineage** and total number of samples tested by hospital

Province	A(H1N1) pdm09	A(H3N2)	A subtype inconclusive	B/ Victoria	B/ Yamagata	B lineage inconclusive	B lineage pending results***	Total samples
Edendale (KZ)	0	0	0	8	0	0	0	629
Helen Joseph-Rahima Moosa (GP)	0	3	0	15	0	1	0	1068
Klerksdorp-Tshepong (NW)	0	0	0	4	0	0	0	680
Mapulaneng-Matikwana (MP)	0	0	0	1	0	0	0	411
Red Cross (WC)	0	0	0	9	0	0	0	535
Mitchell's Plain (WC)	0	1	0	0	0	0	0	626
Tintswalo (MP)	0	0	0	1	0	0	0	169
Total:	0	4	0	38	0	1	0	4 118

GP: Gauteng; KZ: KwaZulu-Natal; NW: North West; MP: Mpumalanga (Tintswalo started enrolling on the 10th Feb 2021); WC: Western Cape
Inconclusive: insufficient viral load in sample and unable to characterise further

**Influenza B (Victoria) was detected in four (3%) of 145 specimens from patients who met suspected SARS-CoV-2 case definition but did not meet pneumonia (SRI) case definition. These are not included in the table.

***influenza B lineage results are pending

INFLUENZA, RESPIRATORY SYNCYTIAL VIRUS AND SARS-CoV-2 SURVEILLANCE REPORT

WEEK 34 2021

REPORTING PERIOD 4 JANUARY 2021 TO 29 AUGUST 2021

NATIONAL SYNDROMIC SURVEILLANCE FOR PNEUMONIA




Figure 10. National syndromic surveillance for pneumonia percentage influenza detections and epidemic thresholds*

*Thresholds based on 2010-2019 data

INFLUENZA, RESPIRATORY SYNCYTIAL VIRUS AND SARS-CoV-2 SURVEILLANCE REPORT

WEEK 34 2021

REPORTING PERIOD 4 JANUARY 2021 TO 29 AUGUST 2021

NATIONAL SYNDROMIC SURVEILLANCE FOR PNEUMONIA




Figure 11. Number of samples testing positive for respiratory syncytial virus* by subgroup and detection rate by week

Inconclusive: insufficient viral load in sample and unable to characterise further

RSV AB: Both RSV A and B subgroup identified

RSV subgroup pending: means RSV results for subgroups are pending

*RSV was detected in six of 145 (4%) specimens from patients who met suspected SARS-CoV-2 case definition but did not meet pneumonia (SRI) case definition. These are not included in the epidemiological curve.

Table 8: Cumulative number of respiratory syncytial virus** subgroups identified and total number of samples tested by hospital

Hospital (Province)	RSVA	RSVB	RSVAB	RSV subgroup inconclusive	RSV subgroup pending*	Total samples
Edendale (KZ)	5	29	0	0	0	629
Helen Joseph-Rahima Moosa (GP)	37	42	0	0	0	1068
Klerksdorp-Tshepong (NW)	8	44	0	2	0	680
Mapulaneng-Matikwana (MP)	20	7	1	0	0	411
Red Cross (WC)	84	43	2	4	1	535
Mitchell's Plain (WC)	37	10	1	1	0	626
Tintswalo (MP)	10	3	0	0	0	169
Total:	201	178	4	7	1	4 118

GP: Gauteng; KZ: KwaZulu-Natal; NW: North West; MP: Mpumalanga (Tintswalo started enrolling on the 10th Feb 2021); WC: Western Cape

Inconclusive: insufficient viral load in sample and unable to characterise further

RSV AB: Both RSV A and B subgroup identified

*RSV results for subgroups are pending

**RSV was detected in six of 145 (4%) specimens from patients who met suspected SARS-CoV-2 case definition but did not meet pneumonia (SRI) case definition. These are not included in the table.

INFLUENZA, RESPIRATORY SYNCYTIAL VIRUS AND SARS-CoV-2 SURVEILLANCE REPORT

WEEK 34 2021

REPORTING PERIOD 4 JANUARY 2021 TO 29 AUGUST 2021

NATIONAL SYNDROMIC SURVEILLANCE FOR PNEUMONIA




Figure 12. Number of samples testing positive for respiratory syncytial virus* by province and detection rate by week

*RSV was detected in six of 145 (4%) specimens from patients who met suspected SARS-CoV-2 case definition but did not meet pneumonia (SRI) case definition. These are not included in the epidemiological curve.

INFLUENZA, RESPIRATORY SYNCYTIAL VIRUS AND SARS-CoV-2 SURVEILLANCE REPORT

WEEK 34 2021

REPORTING PERIOD 2 MARCH 2020 TO 29 AUGUST 2021

NATIONAL SYNDROMIC SURVEILLANCE FOR PNEUMONIA




Figure 13. Number of samples testing positive for SARS-CoV-2** by province and detection rate by week

*Specimens from patients hospitalised with pneumonia at 7 sentinel sites in 5 provinces

**SARS-CoV-2 was detected in 36 of 216 (17%) specimens from patients who met suspected SARS-CoV-2 case definition but did not meet pneumonia (SRI) case definition. These are not included in the epidemiological curve.

Table 9. Cumulative number of identified SARS-CoV-2** and total number of samples tested by hospital

Hospital (Province)	SARS-CoV-2 positive	Total samples tested
Edendale (KZ)	414	1 478
Helen Joseph-Rahima Moosa (GP)	472	1 914
Klerksdorp-Tshepong (NW)	436	1 272
Mapulaneng-Matikwana (MP)	153	713
Red Cross (WC)	56	1 492
Mitchell's Plain (WC)	314	1 096
Tintswalo (MP)	46	168
Total:	1 891	8 133

GP: Gauteng; KZ: KwaZulu-Natal; NW: North West; MP: Mpumalanga (Tintswalo started enrolling on the 10th Feb 2021); WC: Western Cape

**SARS-CoV-2 was detected in 36 of 216 (17%) specimens from patients who met suspected SARS-CoV-2 case definition but did not meet pneumonia (SRI) case definition. These are not included in the table.

INFLUENZA, RESPIRATORY SYNCYTIAL VIRUS AND SARS-CoV-2 SURVEILLANCE REPORT

WEEK 34 2021

REPORTING PERIOD 2 MARCH 2020 TO 29 AUGUST 2021

SUMMARY OF LABORATORY CONFIRMED SARS-COV-2 CASES

Table 10. Characteristics of laboratory-confirmed cases of COVID-19, enrolled in influenza-like illness (ILI) and pneumonia surveillance programmes, South Africa, 02 March 2020 – 29 August 2021

Characteristic	Influenza-like illness (ILI), public-sector, n=669 (%)	Pneumonia, n=1 927 (%)
Age group		
0-9	51/669 (7)	124/1927 (6)
10-19	47/669 (7)	12/1927 (1)
20-39	312/669 (47)	344/1927 (18)
40-59	209/669 (31)	723/1927 (37)
60-79	48/669 (7)	653/1927 (34)
≥80	2/669 (<1)	71/1927 (4)
Sex-female	409/669 (61)	1177/1927 (61)
Province*		
Gauteng	N/A	473/1927 (24)
KwaZulu-Natal	102/669 (15)	419/1927 (22)
Mpumalanga**	84/669 (13)	229/1927 (12)
North West	338/669 (50)	436/1927 (23)
Western Cape	145/669 (22)	370/1927 (19)
Race		
Black	502/666 (75)	1503/1904 (79)
Coloured	133/666 (20)	298/1904 (16)
Asian/Indian	4/666 (1)	47/1904 (2)
White	21/666 (3)	38/1904 (2)
Other	6/666 (1)	18/1904 (1)
Presentation		
Fever	523/666 (79)	891/1904 (47)
Cough	648/666 (97)	1827/1904 (96)
Shortness of breath	238/666 (36)	1494/1904 (78)
Chest pain	286/666 (43)	763/1904 (40)
Diarrhoea	49/666 (7)	116/1904 (6)

INFLUENZA, RESPIRATORY SYNCYTIAL VIRUS AND SARS-CoV-2 SURVEILLANCE REPORT

WEEK 34 2021

REPORTING PERIOD 2 MARCH 2020 TO 29 AUGUST 2021

Characteristic	Influenza-like illness (ILI), public-sector, n=669 (%)	Pneumonia, n=1 927 (%)
Underlying conditions		
Hypertension [§]	17/527 (3)	248/1619 (15)
Cardiac	2/666 (<1)	45/1904 (2)
Lung disease	0/666 (0)	2/1904 (<1)
Diabetes	15/666 (2)	387/1904 (20)
Cancer	1/666 (<1)	11/1904 (1)
Tuberculosis	10/666 (2)	44/1904 (2)
HIV-infection	124/666 (19)	405/1904 (21)
Other ***	12/666 (2)	90/1904 (5)
Management		
Oxygen therapy	9/666 (1)	1398/1904 (73)
ICU admission	N/A	40/1904 (2)
Ventilation	N/A	49/1904 (3)
Outcome***		
Died	0/623 (0)	288/1706 (17)

[§]ILI surveillance not conducted in Gauteng province

**Mpumalanga (ILI site started enrolling on the 10th November 2020 and an additional SARI site started enrolling on the 10th February 2021)

***Chronic lung, liver and kidney disease, organ transplant, pregnancy, malnutrition, obesity, tracheostomy, prematurity, seizure, stroke, anaemia, asplenia, burns, Systemic lupus erythematosus, seizures

****Outcome includes patients who are still hospitalised, have been discharged or referred, and those who died

[§]Data on hypertension was not collected on all cases.

Note: Children may be over-represented amongst hospitalised patients due to the inclusion of a large paediatric hospital in Cape Town.

Of the 288 patients who died, three were in <20 age group, 21 in the 20-39 year age group, 93 in the 40-59 year age group, and 171 were ≥60 years; 168/288 (58%) were female.

Of the 954 hospitalised cases with COVID19 vaccine status, 80 (8%) received vaccine. 8 (10%) received Johnson & Johnson, 58 (73%) received the first dose of Pfizer-BioNTech, 3 (4%) Astra Zeneca and 11 (14%) could not remember the vaccine type received. 13 (16%) of the 80 cases had full vaccination (n=8, J&J and n=5, Pfizer-BioNTech). Cases age varied from 35 years to >60 years old and the majority (74%, 59/80) were >60 years old. Females were a majority 60% (48/80) and 11% (9/80) cases were HIV infected.